# Pembrolizumab

## KEYTRUDA inj 100mg/4mL

##### 臨採

| 藥品代碼   | IKEY1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|:-----------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 適應症     | KEYTRUDA is a human programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and， if BRAF V600 mutation positive， a BRAF inhibitor.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 用法用量   | [Melanoma] 2 mg/kg infused over 30 minutes once every 3 weeks until disease progression or unacceptable toxicity. [Non-Small Cell Lung Cancer (NSCLC)] 200 mg for untreated patients or 2 mg/kg as a single agent for previously treated patients infused over 30 minutes once every 3 weeks until disease progression， unacceptable toxicity， or up to 24 months. [Classical Hodgkin Lymphoma (cHL)， Head and Neck Squamous Cell Cancer (HNSCC)， Urothelial Carcinoma] 200 mg infused over 30 minutes once every 3 weeks until disease progression， unacceptable toxicity， or up to 24 months.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| 肝功能異常 | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 腎功能異常 | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 禁忌       | Hypersensitivity to pembrolizumab or any component of the formulation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| 副作用     | >10%: Cardiovascular: Facial edema (10%) Central nervous system: Fatigue (43%) Dermatologic: Pruritus (28%)， skin rash (24%; immune-mediated: 1%) Endocrine & metabolic: Hyperglycemia (49%)， hypoalbuminemia (37%)， hyponatremia (37%)， hypertriglyceridemia (33%)， decreased serum bicarbonate (22%)， hypocalcemia (21%) Gastrointestinal: Constipation (22%)， nausea (22%)， decreased appetite (20%)， diarrhea (20%)， abdominal pain (13%)， vomiting (13%) Hematologic & oncologic: Anemia (44%; grades 3/4: 10%)， lymphocytopenia (40%; grades 3/4: 9%) Hepatic: Increased serum alkaline phosphatase (26%)， increased serum AST (24%)， increased serum ALT (21%) Neuromuscular & skeletal: Arthralgia (14%) Respiratory: Dyspnea (?20%)， cough (18%) Miscellaneous: Fever (14%) 1% to 10%: Central nervous system: Confusion (>2%)， peripheral neuropathy (2%) Endocrine & metabolic: Hypothyroidism (immune-mediated; 9%)， hyperthyroidism (immune-mediated; 3%) Gastrointestinal: Colitis (immune-mediated; 2%) Immunologic: Antibody development (2%) Neuromuscular & skeletal: Weakness (10%)， arthritis (immune-mediated; 2%) Respiratory: Pneumonitis (3%)， pleural effusion (>2%)， pneumonia (>2%)， respiratory failure (>2%) |
| 孕期建議   | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 哺乳期建議 | No (Limited) Human Data – Potential Toxicity(Mother) 無(很少)資料 – 避免使用(母體)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

